The latest efficacy and progress of tucatinib in clinical studies

Tucatinib is one of the HER2-targeted drugs that has attracted much attention in recent years, especially in the treatment of HER2-positive advanced breast cancer. In the latest announcementHER2CLIMB-02 In phase III clinical studies, tucatinib combined with T-DM1 was used in patients who had previously received trastuzumab and taxanes. The median progression-free survival was ( span>PFS) was extended from 7.4 months to 9.5 months. It is particularly worth mentioning that this combination also shows good therapeutic potential for patients with brain metastases. The median PFS in the brain metastasis subgroup reached 7.8 months, proving its advantages in crossing the blood-brain barrier.

SGNTUC-019 published in "Natural Medicine" in2024 In the phase II study, tucatinib combined with trastuzumab showed good efficacy in the treatment of patients with advanced breast cancer with HER2 mutations (non-amplified HER2 mutations). Data show that the overall response rate reached 41.9%, the median response time was 12.6 months, and the progression-free survival time was 9.5 months. This result is of great significance in the group of patients with HER2 mutations who are ineffective with traditional HER2 targeted drugs, meaning that this drug may become a new treatment option for these patients in the future.

Tucatinib has also achieved a breakthrough in the field of colorectal cancer. According toMOUNTAINEER Phase II study, tucatinib combined with trastuzumab in patients with HER2-positive, RAS wild-type metastatic colorectal cancer achieved 38% The objective response rate of pan> was 12.4 months, and the overall survival (OS) was 24.1 months. The program has now been approved by the FDAApproved for this indication, it fills the gap where no targeted drugs are available for HER2-positive colorectal cancer.

With the continued success of tucatinib in the treatment of breast and colorectal cancer, its potential is being expanded to moreHER2 related solid tumors. Studies are currently exploring the application of tucatinib in HER2 mutated lung cancer, gastric cancer and other diseases, and are also evaluating combination strategies with ADC drugs (such as DS-8201) or immunotherapy. In the future, tucatinib is expected to further expand its indications and become a highly selective HER2-targeted drug covering multiple cancer types, improving the overall level of precision tumor treatment.

Reference materials:https://www.drugs.com/